Nyxoah announced today that it closed a series of financings that amount to up to approximately $77 million in proceeds.

ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.

Mayo Clinic doctors tap into AI technology to detect and treat women with sleep apnea, a disorder that's often misdiagnosed ...